In November, Allergan, a Botox maker, announced that it had accepted a $66 billion takeover bid from Actavis. Actavis is a specialty pharmaceutical company focused on developing, manufacturing and commercializing generic and innovative branded pharmaceutical products.
After the sale closes, members from Actavis and Allergen will constitute the senior management. Additionally, Allergan President Douglas Ingram will continue as a special advisor, according to the report.
More articles on gastroenterology:
Dr. Sonia Kupfer meets with National Institute of Diabetes and Digestive and Kidney Diseases
Newman Regional Health to acquire $345k endoscopy system
New EndoChoice slim scope, US Endoscopy distribution agreement & more – 6 GI/endoscopy company key notes
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
